Stockhead: Racura Oncology opens Hong Kong site in “cautious” trial rollout

Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. The company hopes that as well as attacking the tumours, RC220 will protect the heart against the dangerous effects of chemotherapy.

Read the full article here.